Arrowhead Pharmaceuticals Corp (ARWR) Misses Q1 EPS by 41c, Revenues Miss
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $66.48 -1.86%
Financial Fact:
TOTAL OTHER INCOME (EXPENSE): -79.26K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Financial Fact:
TOTAL OTHER INCOME (EXPENSE): -79.26K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q1 EPS of $0.13, $0.41 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $34.66 million versus the consensus estimate of $71.6 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold
- DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
